Indefinite Delivery Contract VA25913D0313

The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse (NIDA) awarded a single-award $21 million indefinite delivery contract to Altasciences Clinical Kansas Inc., a contract research organization, to conduct pharmacokinetic and pharmacodynamic trials for medication development in substance use disorders. Under this contract, NIDA issued a $1,838,615 firm fixed price delivery order to Altasciences to perform Phase 1 cocaine drug interaction...

The Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) has awarded a single-award indefinite delivery contract to Polypeptide Laboratories San Diego, LLC, a Contract Development & Manufacturing Organization (CDMO), to provide chemistry, manufacturing, and controls (CMC) services for the development of drug substances. This five-year, $49.7 million IDV contract, awarded without set-asides, supports NCATS'...

The National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services, awarded a $7 million indefinite delivery contract to Murty Pharmaceuticals, Inc., a small disadvantaged minority-owned business, for the development and manufacture of pharmaceutical products to support NIDA's substance abuse and addiction treatment research programs. Under this contract, Murty Pharmaceuticals performs a range of services including formulation development,...

The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded an indefinite delivery contract to Pharmaceutical Research Associates Inc., doing business as PRA, with a potential value of $250 million. The contract provides for clinical trials planning and execution services in support of the Clinical Studies Network. PRA was issued a $200,000 delivery order for one base year of performance ending September 2021 to conduct clinical trial...

This $49.9 million Indefinite Delivery Contract was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO) subsidiary of Thermo Fisher Scientific. The contract is for research and development related to clinical studies under NIDA's Blueprint MedTech program, which focuses on medical technology development for nervous system disorders. Under this IDC, PPD will provide a range of services including developing...

The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery contract to We Pharma, Inc., doing business as WEP Clinical, with a potential value of $9.5 million. The contract has no set-aside designation and is a single-award arrangement to provide currently marketed drug products for FDA research studies from September 2020 through September 2025. Under this contract, WEP Clinical has received multiple firm fixed price delivery orders to supply...

This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Alchem Laboratories Corporation. The contract, valued at up to $17,891,012, is to provide CRO (contract research organization) support services for NCATS's Medicinal Chemistry for Lead Optimization program. Under this multiple-award IDC, Alchem Laboratories will perform a variety of preclinical and...

The National Institute on Drug Abuse (NIDA), a civilian agency within the Department of Health and Human Services, awarded a single-award Indefinite Delivery Contract (IDC) to Polypeptide Laboratories San Diego, LLC (doing business as Polypeptide Labs) in February 2022. The $2,781,317 contract covers the synthesis and distribution of opioid and related peptides over a 5-year period of performance from February 15, 2022 to February 14, 2027. Polypeptide Labs, a specialized manufacturer of...

Altasciences Clinical Kansas Inc. was awarded a single-award indefinite delivery contract from the Department of Health and Human Services Food and Drug Administration valued at up to $5 million. The contract aims to advance generic drug approvals through the conduct of bioequivalence studies and characterization of generic drugs. Three firm fixed price delivery orders have been issued against this contract to date, with places of performance in Overland Park, Kansas. The first delivery order,...

This indefinite delivery contract (IDC) was awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Eurofins Discovery Services North America, LLC, a foreign-owned for-profit contract research organization. The $20 million single-award IDC is for research and development services and studies, with a period of performance through September 2028. Under this IDC, Eurofins has been issued two firm-fixed-price delivery orders. The first order, valued at $38,639.60, is for...